Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Prospekta-VET** (formerly known as **Anoten**) is an approved veterinary neuroimmunobiological drug developed by Materia Medica Lifesciences for dogs and cats. It is formulated as an oral powder containing affinity-purified, modified antibodies to the brain-specific S-100 protein in a release-active form. Prospekta-VET is indicated for the normalization of animal behavior, alleviation of stress and anxiety symptoms, and facilitation of adaptation to new environments, transportation, grooming, or veterinary interventions. By modulating the functional activity of the S-100 protein, the drug regulates synaptic transmission, neuronal plasticity, and the balance between excitatory and inhibitory neurotransmitter systems in the central nervous system, providing anxiolytic, nootropic, and neuroprotective effects without causing sedation or muscle relaxation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Prospekta-VET.